ArticleBiomedical chromatography : BMC2026
LC-MS/MS Determination of Crotonoside in Rat Plasma and Application to Pharmacokinetic Study.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crotonoside, a main bioactive component in Croton tiglium L., exhibits promising antitumor and immunological activities. This study developed and validated a rapid, sensitive LC-MS/MS method for the quantification of crotonoside in rat plasma. The mobile phase was 0.1% formic acid aqueous solution-acetonitrile (50:50, v/v) with a flow rate of 0.2 mL/min. Rats were randomly divided into two groups for intragastric and intravenous administration, respectively. Protein precipitation by acetonitrile was used to separate crotonoside from the plasma samples. The samples were analyzed using a validated method. Method validation included linearity, precision, accuracy, recovery, matrix effect, and sample stability. The linear range of crotonoside was 20-10,000 ng/mL. Recoveries ranged 93.5%-101.7% with precision (RSD ≤ 7.7%). Matrix effects and stability were acceptable. Crotonoside pharmacokinetics after intragastric administration were as follows: maximum drug concentration (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.